Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis.

Neil A ZakaiRob F WalkerRichard F MacLehoseInsu KohAlvaro AlonsoPamela L Lutsey

Published in: Research and practice in thrombosis and haemostasis (2021)

These data suggest that apixaban has a lower recurrent VTE hospitalization rate than rivaroxaban during the secondary prevention of VTE, and further study of diverse patient populations, especially by kidney function, is warranted.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
electronic health record
big data
machine learning
free survival
pulmonary embolism